Literature DB >> 19863864

Characterization and treatment of resistant hypertension.

Roberto Pisoni1, Mustafa I Ahmed, David A Calhoun.   

Abstract

Resistant hypertension is a common medical problem. It carries a significantly increased risk of end-organ damage and cardiovascular events compared with more easily controlled hypertension. Resistant hypertension is most often related to isolated systolic hypertension and is characterized by aldosterone excess and increased intravascular volume. Its diagnosis requires the exclusion of pseudoresistance. The etiology of resistant hypertension is almost always multifactorial. Common reversible contributing factors need to be identified and addressed. Secondary causes of hypertension, such as primary aldosteronism, parenchymal and vascular kidney disease, and obstructive sleep apnea, require investigation and effective treatment if present. Therapy for resistant hypertension should be based on use of rational drug class combinations at optimal doses, with particular attention to adequate diuretic use. The addition of an aldosterone antagonist may further improve blood pressure control.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19863864      PMCID: PMC2806815          DOI: 10.1007/s11886-009-0059-z

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  45 in total

Review 1.  Clinical practice. Resistant or difficult-to-control hypertension.

Authors:  Marvin Moser; John F Setaro
Journal:  N Engl J Med       Date:  2006-07-27       Impact factor: 91.245

2.  An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial.

Authors:  Karl A Illig; Mark Levy; Luis Sanchez; Gregory D Trachiotis; Charles Shanley; Eric Irwin; Terry Pertile; Robert Kieval; Robert Cody
Journal:  J Vasc Surg       Date:  2006-12       Impact factor: 4.268

3.  Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.

Authors:  Michael E Ernst; Barry L Carter; Chris J Goerdt; Jennifer J G Steffensmeier; Beth Bryles Phillips; M Bridget Zimmerman; George R Bergus
Journal:  Hypertension       Date:  2006-01-23       Impact factor: 10.190

4.  Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.

Authors:  Suzanne Oparil; Steven A Yarows; Samir Patel; Hui Fang; Jack Zhang; Andrew Satlin
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321

5.  Increased sodium intake correlates with greater use of antihypertensive agents by subjects with chronic kidney disease.

Authors:  Neil Boudville; Sharon Ward; Mark Benaroia; Andrew A House
Journal:  Am J Hypertens       Date:  2005-10       Impact factor: 2.689

6.  Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension.

Authors:  Sante D Pierdomenico; Domenico Lapenna; Anna Bucci; Roberta Di Tommaso; Rocco Di Mascio; Bianca M Manente; Maria P Caldarella; Matteo Neri; Franco Cuccurullo; Andrea Mezzetti
Journal:  Am J Hypertens       Date:  2005-11       Impact factor: 2.689

7.  Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension.

Authors:  Monique N Pratt-Ubunama; Mari K Nishizaka; Robyn L Boedefeld; Stacey S Cofield; Susan M Harding; David A Calhoun
Journal:  Chest       Date:  2007-02       Impact factor: 9.410

8.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

Review 9.  Hypertension in renal parenchymal disease: why is it so resistant to treatment?

Authors:  V M Campese; N Mitra; D Sandee
Journal:  Kidney Int       Date:  2006-03       Impact factor: 10.612

Review 10.  Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.

Authors:  Juan P Casas; Weiliang Chua; Stavros Loukogeorgakis; Patrick Vallance; Liam Smeeth; Aroon D Hingorani; Raymond J MacAllister
Journal:  Lancet       Date:  2005-12-10       Impact factor: 79.321

View more
  13 in total

1.  Endovascular radiofrequency renal denervation in treating refractory arterial hypertension: a preliminary experience.

Authors:  G Simonetti; A Spinelli; R Gandini; V Da Ros; E Gaspari; I Coco; M De Francesco; D Santucci; N Di Daniele; R Lauro
Journal:  Radiol Med       Date:  2012-01-07       Impact factor: 3.469

2.  Incidence and prognosis of resistant hypertension in hypertensive patients.

Authors:  Stacie L Daugherty; J David Powers; David J Magid; Heather M Tavel; Frederick A Masoudi; Karen L Margolis; Patrick J O'Connor; Joe V Selby; P Michael Ho
Journal:  Circulation       Date:  2012-02-29       Impact factor: 29.690

3.  Age- and gender-related characteristics of obstructive sleep apnea.

Authors:  Itay E Gabbay; Peretz Lavie
Journal:  Sleep Breath       Date:  2011-04-16       Impact factor: 2.816

4.  Resistant hypertension and obstructive sleep apnea in the setting of kidney disease.

Authors:  Khaled Abdel-Kader; Sheena Dohar; Nirav Shah; Manisha Jhamb; Steven E Reis; Patrick Strollo; Daniel Buysse; Mark L Unruh
Journal:  J Hypertens       Date:  2012-05       Impact factor: 4.844

5.  The association between medication adherence and treatment intensification with blood pressure control in resistant hypertension.

Authors:  Stacie L Daugherty; J David Powers; David J Magid; Frederick A Masoudi; Karen L Margolis; Patrick J O'Connor; Julie A Schmittdiel; P Michael Ho
Journal:  Hypertension       Date:  2012-06-25       Impact factor: 10.190

6.  Overview of resistant hypertension: A glimpse of the cardiologist's current standpoint.

Authors:  Luis Paiva; Maria Carmo Cachulo; Rui Providencia; Sergio Barra; Paulo Dinis; Antonio Leitao-Marques
Journal:  World J Cardiol       Date:  2012-09-26

7.  Does experimental paradoxical sleep deprivation (EPSD) is an appropriate model for evaluation of cardiovascular complications of obstructive sleep apnea?

Authors:  Siyavash Joukar; Soodabe Ghorbani-Shahrbabaki
Journal:  Sleep Breath       Date:  2015-12-30       Impact factor: 2.816

8.  Common secondary causes of resistant hypertension and rational for treatment.

Authors:  Charles Faselis; Michael Doumas; Vasilios Papademetriou
Journal:  Int J Hypertens       Date:  2011-03-02       Impact factor: 2.420

9.  Non drowsy obstructive sleep apnea as a potential cause of resistant hypertension: a case report.

Authors:  Aibek E Mirrakhimov
Journal:  BMC Pulm Med       Date:  2012-05-17       Impact factor: 3.317

10.  Characteristics and future cardiovascular risk of patients with not-at-goal hypertension in general practice in France: the AVANT'AGE study.

Authors:  Yi Zhang; Hélène Lelong; Sandrine Kretz; Davide Agnoletti; Jean-Jacques Mourad; Michel E Safar; Jacques Blacher
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-03-07       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.